LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

Home・Elenco Azioni・Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals Inc

Chiusa

SettoreSettore sanitario

46.13 -1.64

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

45.77

Massimo

46.38

Metriche Chiave
By Trading Economics
Entrata	36M -2.3M
Vendite	-3.9M 208M
P/E Media del settore	48.435 50.102
EPS	0.21
Margine di Profitto	-1.104
Dipendenti	778
EBITDA	-72M 19M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+35.88% upside

Dividendi
By Dow Jones
Utili prossimi	4 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-2.1M 2.8B
Apertura precedente	47.77
Chiusura precedente	46.13

Notizie sul Sentiment di mercato

By Acuity

14%

86%

19 / 344 Classifica in Healthcare

Supernus Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

29 mag 2026, 23:08 UTC

Acquisizioni, Fusioni, Takeovers

Family Offices Bypass Private Equity and Go Direct -- Barrons.com

29 mag 2026, 23:06 UTC

Acquisizioni, Fusioni, Takeovers

After a Series of Sales, Hims Director Buys Company Shares -- Barrons.com

29 mag 2026, 20:53 UTC

Utili

Oil Declines Lift Stocks to Fresh Records -- WSJ

29 mag 2026, 20:50 UTC

Discorsi di Mercato

Health Care Roundup: Market Talk

29 mag 2026, 20:33 UTC

Discorsi di Mercato

Canada Meets Only One of Three Criteria To Declare Recession -- Market Talk

29 mag 2026, 20:11 UTC

Utili

Okta Stock Soars. What's Stealing the Show From Earnings. -- Barrons.com

29 mag 2026, 19:47 UTC

Utili

These Were the Best and Worst S&P 500 Stocks in May -- Barrons.com

29 mag 2026, 19:36 UTC

Discorsi di Mercato

U.S. Natural Gas Futures End Month With Gains -- Market Talk

29 mag 2026, 19:34 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

29 mag 2026, 19:34 UTC

Discorsi di Mercato

Over Half of Canadian Industries Growing, Undermining Recession Talk -- Market Talk

29 mag 2026, 19:22 UTC

Discorsi di Mercato

Oil Falls as U.S., Iran Expected to Reach Agreement -- Market Talk

29 mag 2026, 19:05 UTC

Acquisizioni, Fusioni, Takeovers

Universal Music Group Rejects $65 Billion Takeover Bid From Bill Ackman's Pershing Square -- Barrons.com

29 mag 2026, 18:19 UTC

Discorsi di Mercato

Canada Technical Recession Chatter Rife But Per-Capita GDP Was Up -- Market Talk

29 mag 2026, 18:12 UTC

Acquisizioni, Fusioni, Takeovers

Universal Music Group Rejects $65 Billion Buyout Offer From Bill Ackman -- WSJ

29 mag 2026, 18:11 UTC

Discorsi di Mercato

Canada Households Reaching Limit at Keeping Spending in Positive Territory -- Market Talk

29 mag 2026, 18:10 UTC

Discorsi di Mercato

As BTC Long-Term Holders Rise, Short-Term Holders Flee -- Market Talk

29 mag 2026, 17:55 UTC

Utili

Okta Stock Soars. What's Stealing the Show From Earnings. -- Barrons.com

29 mag 2026, 17:55 UTC

Discorsi di Mercato

NEAR Protocol Nearly Doubles in May -- Market Talk

29 mag 2026, 17:38 UTC

Discorsi di Mercato

U.S. Oil Rig Count Rises for Fifth Straight Week -- Market Talk

29 mag 2026, 17:00 UTC

Utili

Okta Stock Soars After Earnings. Results Aren't the Real Catalyst. -- Barrons.com

29 mag 2026, 16:20 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

29 mag 2026, 16:20 UTC

Discorsi di Mercato

Health Care Roundup: Market Talk

29 mag 2026, 16:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

29 mag 2026, 16:02 UTC

Discorsi di Mercato

Gold Extend Gains as Investors Await U.S.-Iran Deal News -- Market Talk

29 mag 2026, 15:55 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

29 mag 2026, 15:55 UTC

Discorsi di Mercato

Cryptocurrencies Appear Detached From Stocks -- Market Talk

29 mag 2026, 15:50 UTC

Acquisizioni, Fusioni, Takeovers

Johnson Matthey CEO: Cormetech Acquisition to Drive Growth

29 mag 2026, 15:50 UTC

Acquisizioni, Fusioni, Takeovers

Johnson Matthey CEO: Demand for AI Data Centers Insatiable

29 mag 2026, 15:40 UTC

Discorsi di Mercato

Kalshi To Launch Crypto Perpetual Futures -- Market Talk

29 mag 2026, 15:20 UTC

Discorsi di Mercato

Canada's Economy Not Looking All That Bright -- Market Talk

Confronto tra pari

Modifica del prezzo

Supernus Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

35.88% in crescita

Previsioni per 12 mesi

Media 62.75 USD 35.88%

Alto 66 USD

Basso 55 USD

Basato su 4 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Supernus Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

4 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 4 che hanno fornito valutazioni azionarie a Supernus Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

19 / 344 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.